Bispecific ERK5 Degraders Using E3 Ligase Recruitment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current small molecule inhibitors for ERK5 are limited in their effectiveness and efficiency, necessitating a more targeted and efficient method to degrade ERK5 for treating cancer and inflammatory diseases.
Innovation Solution
Development of bispecific compounds that conjugate a targeting ligand for ERK5 with an E3 ligase binder, utilizing the ubiquitin/proteasome system to selectively degrade ERK5, thereby reducing the need for high intracellular concentrations of ERK5 inhibitors.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional small molecule inhibitors are used to inhibit ERK5, then ERK5 activity is suppressed, but high intracellular concentrations are required and effectiveness is limited
Solution Approach 1:
The patent employs a bispecific compound as an intermediary that bridges the targeting ligand (which binds ERK5) and the E3 ligase binder (which recruits the degradation machinery). This intermediary structure enables the formation of a ternary complex that brings the target protein into proximity with the degradation system, resolving the limitation of traditional inhibitors that require high concentrations to achieve sufficient target suppression.
Solution Approach 2:
The invention leverages the cell's endogenous ubiquitin-proteasome degradation system to eliminate ERK5. Instead of relying on external inhibitors that must maintain high concentrations to block ERK5 activity, the bispecific compound recruits the cell's own protein degradation machinery to selectively degrade ERK5, thereby achieving reliable inhibition through the body's natural protein disposal pathways.
2Productivity
If traditional ERK5 inhibitors are used, then some ERK5 suppression is achieved, but the method lacks efficiency and requires high doses
Solution Approach 1:
The bispecific compound serves as a molecular intermediary that simultaneously binds to ERK5 (via the targeting ligand) and to E3 ligase (via the E3 ligase binder). This dual-binding capability creates a bridge that efficiently recruits the degradation system to the target protein, dramatically improving the efficiency of ERK5 suppression compared to traditional inhibitors that rely on direct competitive inhibition requiring high doses.
Solution Approach 2:
The invention harnesses the cell's intrinsic ubiquitin-proteasome system to efficiently degrade ERK5. By recruiting this endogenous degradation machinery through the E3 ligase binder component, the system achieves high-efficiency ERK5 suppression at low doses, as the cell's own protein quality control apparatus is redirected to eliminate the target protein.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The bispecific compounds effectively degrade ERK5 at lower concentrations than traditional inhibitors, providing a potential therapeutic modality for ERK5-associated diseases and disorders, including cancer and inflammation.
Implementation Method 1
utilizing the ubiquitin/proteasome system to selectively degrade ERK5
Data Source
Figure 1
Figure 2
Figure 3
AI summary
Disclosed are bispecific compounds (degraders) that target ERK5 for degradation. Also disclosed are pharmaceutical compositions containing the degraders and methods of using the compounds to treat cancer and inflammatory diseases.